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The human ErbB, or epidermal growth factor receptor (EGFR), is a family of four structurally related receptor 
tyrosine kinases—ErbB-1 or EGFR, ErbB-2 or HER2/neu, 
ErbB-3 or HER3, and ErbB-4 or HER4. Ligand binding to the 
receptor induces receptor homo or heterodimerization with 
other ErbB family members or with other extracellular recep-
tors. Receptor activation signals key downstream pathways 
that regulate cell proliferation, differentiation, and survival.
The EGFR pathway has been extensively investigated in 
non–small-cell lug cancer (NSCLC) patients. Overexpression 
of EGFR has been reported in 50% to 80% of NSCLC patients, 
and activating mutations within the EGFR kinase domain 
have been detected in up to 17% of North American patients 
diagnosed with metastatic lung adenocarcinoma.1 EGFR tyro-
sine kinase inhibitors (TKIs) are approved as second- or third-
line therapy in unselected patients with advanced NSCLC. 
However, recent studies have demonstrated improved response 
rate (RR) and progression-free survival (PFS) in patients with 
EGFR mutation-positive NSCLC treated with an EGFR TKI 
before chemotherapy.2–6 HER2 kinase domain mutations are 
less common in NSCLC and are found in approximately 2% 
to 4% of patients with metastatic lung adenocarcinoma.1 The 
efficacy of HER2 inhibitors in this setting is yet to be deter-
mined, however, there is a single case report of a patient with 
HER2 mutant NSCLC, who responded to weekly trastuzumab 
(the anti-HER2 antibody) with paclitaxel.7
SUMMARY OF PRESENTATIONS
Second-Generation EGFR TKIs and Acquired  
Resistance to EGFR TKIs
All patients with EGFR mutant tumors treated 
with EGFR TKIs eventually develop acquired resistance. 
Approximately 50% of patients have tumors that harbor a sec-
ond-site mutation within the EGFR kinase domain, the most 
common of which involves a threonine to methionine change 
at position 790 (T790M).8,9 Other mechanisms of acquired 
resistance have been described.10 At the time of progression, 
there are as of now no approved targeted therapies.
Afatinib (BIBW2992) is an irreversible Pan-ErbB 
inhibitor. Dr. Mok presented the LUX-Lung Program. LUX-
Lung I was a randomized phase IIb/III trial in NSCLC 
patients who progressed after at least 12 weeks of erlo-
tinib or gefitinib. Patients treated with afatinib had a higher 
RR and PFS as compared with those treated with placebo. 
However, median overall survival was lower for afatinib-
treated patients (10.8 versus 12.0 months). LUX-Lung II 
was a phase II trial of first-line afatinib in EGFR mutation-
positive NSCLC patients and reported a PFS of 10.1 months. 
LUX-Lung III and IV both compare first-line afatinib with 
chemotherapy (cisplatin/pemetrexed or cisplatin/gem-
citabine) in EGFR mutation-positive NSCLC. Data from 
LUX-Lung IV are expected within the year. LUX-Lung V is 
randomized phase III trial comparing chemotherapy with or 
without afatinib in patients who have progressed on erlotinib 
or gefitinib. LUX-Lung VII is a phase IIb trial of first-line 
afatinib compared with gefitinib in EGFR mutation-positive 
patients, and LUX-Lung VIII is a randomized phase III trial 
of afatinib versus erlotinib in squamous cell lung cancer 
patients. A phase I b trial, based on preclinical data suggest-
ing that combination afatinib and cetuximab is efficacious 
in EGFR mutant lung cancer patients who have developed 
acquired resistance to erlotinib or gefitinib, was presented 
by Dr. Horn. This trial demonstrated a 40% RR and 93% 
disease control in the first 91 patients enrolled. PFS is not 
mature.
Dacomitinib is an irreversible Pan-ErbB inhibitor. Dr. 
Miller presented a trial of dacomitinib in never or former 
light smokers who were Asian, or whose tumors were either 
KRAS wild-type (wt), or EGFR mutated. Forty-six percent 
of enrolled patients had an EGFR mutation, RR was 42%, 
and disease control was 86% (55% and 94%, respectively in 
EGFR mutation-positive patients). PFS is not mature. A phase 
II trial comparing dacomitinib with erlotinib in 188 patients 
with advanced NSCLC favored dacomitinib with a median 
PFS of 3.0 versus 2.0 months. The PFS was 3.8 versus 2.0 
months in the KRAS wt cohort and OS was 9.9 versus 7.7 
months. The phase III Archer trial comparing dacomitinib 
with erlotinib as second- or third-line therapy for patients with 
advanced NSCLC is ongoing.
CO1686 is an oral small-molecule mutant-selective 
irreversible inhibitor of EGFR. Dr. Camidge reported on two 
phase I/II trials with CO1686, which are currently open or in 
development; a phase I trial for patients with known EGFR 
mutations is open in the dose-escalation phase, and a trial for 
patients who are T790M positive will open in the expansion 
phase. AZD8931 is an oral small-molecule pan-ErbB inhibi-
tor. Dr. Nash presented phase I studies with AZD8931 alone 
in all patients with advanced malignancies and in combination 
with paclitaxel in breast cancer patients. MM151 is an oligo-
clonal therapeutic consisting of a mixture of three fully human 
monoclonal antibodies designed to bind to nonoverlapping 
epitopes of EGFR. Dr. Nielsen presented preclinical data on 
this agent that is currently in early phase I clinical trials.
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Small-Molecule Inhibitors and HER2
Afatinib in HER2 positive NSCLC was presented by Dr. 
Chand. A phase II trial of single-agent afatinib in HER2 posi-
tive NSCLC patients is ongoing. Dr. Kris presented an ongo-
ing phase II trial of dacomitinib in NSCLC patients who are 
either EGFR mutation positive, HER2 mutation positive, or 
HER2 amplified. ARRY380 is a small-molecule inhibitor of 
HER2. Dr. Winkler presented a phase I dose-escalation study 
of ARRY380 that established an maximum tolerated dose of 
600 mg twice daily. This dose has been administered to an 
expansion cohort of patients with metastatic breast cancer. Dr. 
Winkler queried the audience as to whether there is need to 
evaluate ARRY380 in NSCLC patients with activating HER2 
mutations. Neratinib (HKI272) is an irreversible Pan-ErbB 
inhibitor. Dr. Gandhi presented a phase I trial of neratinib and 
temsirolimus (a mammalian target of rapamycon inhibitor) in 
HER2 mutant NSCLC patients with encouraging clinical activ-
ity—disease control in five of six evaluable HER2 NSCLC 
patients and median time to progression of 5.62 months.
Antibodies
HER1/EGFR
Cetuximab is a monoclonal antibody that was shown to 
improve overall survival when added to chemotherapy (cis-
platin/vinorelbine) in patients with stage IV NSCLC.11 Dr. 
Herbst provided an update on open NSCLC trials evaluat-
ing cetuximab. Dr. Hirsch discussed the reproducibility of 
TABLE 1.  Ongoing Clinical Trials of HER1–3 targeting agents in NSCLC
Drug Target
Mode of 
Administration Studies Open to Enrollment
Small-Molecule Inhibitors
Afatinib HER1–3 Oral NCT00809133a
NCT01480141a
NCT01466660
NCT01156545
NCT01523587
NCT00993499
NCT01542437
NCT01090011
NCT01074177
Dacomitinib HER 1–3 Oral NCT01360554
NCT01465802
NCT00818441
CO1686 EGFR and T790M Oral NCT01526928a
AZD8931 HER2 and HER3 None
MM151 HER1/EGFR IV NCT01520389a
ARRY380 HER2 Oral None
Neratinib HER2 Oral None
Antibodies
Cetuximab HER1/EGFR IV NCT01109524
NCT00408499
NCT00946712
NCT01263782
NCT01059188
NCT01212627
NCT00985855
NCT01102231
NCT00842712
NCT01090011
NCT01451632a
NCT01184482a
Necitumumab EGFR IV None
MM302 HER2 IV None
MM111 HER2 IV NCT01304784a
AVO203 HER3 IV None
MM121 HER3 IV NCT00994123
NCT01447225a
NCT01451632a
NCT00734305a
NCT01436565a
U3-1287 HER3 IV NCT01211483
aDenotes phase I trial.
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immunohistochemistry scores and staining for EGFR. He 
also presented on necitumumab, a fully human IgG1 mono-
clonal antibody directed against EGFR currently in phase III 
clinical trials; the INSPIRE trial has closed because of safety 
concerns whereas the SQUIRE trial, a randomized phase III 
study of cisplatin/gemcitabine with or without necitumumab 
in patients with squamous carcinoma of the lung, remains 
open.
HER2
Two antibodies that target HER2 were presented by Dr. 
Nielsen. MM302, a nanotherapeutic encapsulation of doxo-
rubicin with attached HER2 antibodies that are designed to 
target MM302 specifically to cells with HER2 overexpres-
sion. Phase I trials of this agent, in patients with breast cancer, 
are ongoing. MM111, a biospecific antibody that targets cells 
that overexpress HER2 is also in phase I trials in combina-
tion with other HER2 inhibitors and chemotherapy in patients 
with solid tumors. A randomized phase II trial with trastu-
zumab and paclitaxel with or without MM111 in breast cancer 
patients is ongoing.
HER3
AVO-203 is a humanized ErbB-3 inhibitor antibody. 
Dr. Vincent presented preclinical data demonstrating potent 
in vitro and in vivo antitumor activity. The company will be 
filing for an investigational new drug in 2012. MM121 is a 
fully humanized IgG2 antibody with high affinity for ErbB-
3. Dr. Sequist presented a phase I study of MM121 in combi-
nation with erlotinib, which has been completed and will be 
presented later this year. A phase II trial of erlotinib, with or 
without MM121, is ongoing with three patient cohorts: (1) 
EGFR mutation positive; and (2) EGFR wt cohorts will be 
randomized to erlotinib with or without MM121, (3) patients 
with acquired resistance to erlotinib will be treated with 
erlotinib + MM121. U3-1287 is a fully humanized anti-HER 
monoclonal antibody. Dr. von Pawel presented on a phase Ib/
II trial of combination erlotinib and U3-1297. The phase Ib 
portion of the trial reported a best response of stable disease 
in four patients, lasting from 83 to 117 days. The phase II 
trial of erlotinib with or without U3-1287 is ongoing with a 
planned enrollment of 195 patients.
FUTURE DIRECTIONS
The HER family of receptors remains an important 
target in lung cancer. Agents that effectively overcome or 
delay acquired resistance in EGFR mutation-positive NSCLC 
patients with acceptable toxicities are still needed. HER2 rep-
resents a relatively new target in NSCLC patients, and the role 
of antibodies versus TKIs remains to be determined. Acquired 
resistance will also emerge as an issue in this patient popula-
tion. The role of HER3 antibodies in the treatment of lung 
cancer patients remains under active investigation.
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